TABLE 3.
Base Case Outcomes over Lifetime
| Outcome (Discounted per Patient, Unless Otherwise Specified) | IAI 2q8 | Rq4 | Ranibizumab 0.5 mg PRN |
|---|---|---|---|
| Clinical outcomes | |||
| Life-years (undiscounted) | 8.076 | 8.075 | 8.071 |
| QALYs | 5.440 | 5.440 | 5.404 |
| Cost outcomes, $ | |||
| Treatment acquisition | 29,593 | 42,886 | 29,519 |
| Treatment monitoring | 3,022 | 4,006 | 2,881 |
| Blindness | 1,130 | 1,139 | 1,251 |
| Total cost, $ | 33,745 | 48,031 | 33,652 |
| Incremental outcomes (IAI 2q8 vs. comparator) | |||
| QALYs | 0.0 | 0.036 | |
| Costs, $ | -14,286 | 93 | |
| ICER ($ per QALY gained) | Less costly, equal efficacy | 2,583 | |
ETDRS = Early Treatment Diabetic Retinopathy Study; IAI 2q8 = intravitreal aflibercept injection 2 mg every 4 weeks (monthly) for the first 12 weeks (3 months), followed by IAI 2 mg once every 8 weeks; ICER = incremental costeffectiveness ratio; PRN = pro re nata (i.e., as needed); QALYs =quality-adjusted life-years; Rq4 = ranibizumab 0.5 mg monthly.